

Cite this: *RSC Chem. Biol.*, 2021, 2, 1661

# Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors†

Anselm F. L. Schneider,<sup>a</sup> Joerg Kallen,<sup>b</sup> Johannes Ottl,<sup>b</sup> Patrick C. Reid,<sup>c</sup> Sebastien Ripoche,<sup>b</sup> Stephan Ruetz,<sup>b</sup> Therese-Marie Stachyra,<sup>b</sup> Samuel Hintermann,<sup>b</sup> Christoph E. Dumelin,<sup>b</sup> Christian P. R. Hackenberger<sup>b,\*ad</sup> and Andreas L. Marzinzik<sup>b,\*b</sup>

Mouse double minute 2 homolog (**MDM2**, Hdm2) is an important negative regulator of the tumor suppressor **p53**. Using a mRNA based display technique to screen a library of  $>10^{12}$  *in vitro*-translated cyclic peptides, we have identified a macrocyclic ligand that shows picomolar potency on **MDM2**. X-Ray crystallography reveals a novel binding mode utilizing a unique pharmacophore to occupy the Phe/Trp/Leu pockets on **MDM2**. Conjugation of a cyclic cell-penetrating peptide (cCPP) to the initially non cell-permeable ligand enables cellular uptake and a pharmacodynamic response in **SJSA-1** cells. The demonstrated enhanced intracellular availability of cyclic peptides that are identified by a display technology exemplifies a process for the application of intracellular tools for drug discovery projects.

Received 16th March 2021,  
Accepted 21st August 2021

DOI: 10.1039/d1cb00056j

rsc.li/rsc-chembio

## Introduction

Protein–protein interactions (PPIs) are essential networks for numerous biological processes and play a key role in all living organisms. Not surprisingly, PPIs have been very attractive for drug discovery targets during the last decades.<sup>1</sup> Targeting PPIs is challenging due to the large, shallow, or weakly defined areas for ligand interaction, which are not well suited for small molecules (200–500 Da). Those interaction surfaces are typically highly hydrophobic with few distinct pockets making it difficult for a rule-of-five compliant small molecule to bind. Nonetheless, significant advances in novel technologies like fragment based drug discovery and high throughput screening have demonstrated that low molecular weight starting points for medicinal chemistry can be successfully developed into clinical candidates<sup>2</sup> and become effective drugs.<sup>3</sup> Antibodies as well as smaller fragments are well known to bind larger surfaces and have been successful in addressing targets which are difficult for small molecules;<sup>4</sup> however, their intracellular transport is hampered and therefore often limited to extracellular PPIs.<sup>5</sup>

Restoring the critical gatekeeper **p53** in response to cellular damage and stress by blocking the **p53/MDM2** interaction has become a very promising PPI target in cancer research. As it is one of the best characterized intracellular PPI targets with well-established biochemical and cellular assays, various highly potent and selective scaffolds disrupting the **p53/MDM2** interaction have been developed. Those inhibitors show high potency in biochemical as well as cellular assays translating into efficacy models.<sup>6</sup> One of those development candidates serves as a benchmark for our study developing peptides modulating an intracellular response.<sup>7</sup>

Linear peptides compared to wild type **p53** have been discovered early on from phage displayed libraries, but those bear challenges in terms of potency, cell penetration and stability.<sup>8</sup> In respect of superior potency and stability macrocyclic peptides are considered an appropriate modality to address the ligandability of such difficult targets, but also possess challenges concerning cell penetration. Stapled  $\alpha$ -helical peptides emerged as a new modality to address intracellular PPIs about a decade ago and have been developed into clinical candidates for **p53** dependent cancers.<sup>9,10</sup> On the other hand, stapling peptides does not necessarily enhance affinity nor biological response by default and substantial optimization cycles from a known natural sequence are necessary to engineer highly affine molecules with a biological response in cellular studies.<sup>11,12</sup> Alternatively, the attachment of a cyclic cell-penetrating peptide (cCPP) demonstrated an enhanced cellular delivery of a stapled peptidyl inhibitor against the **MDM2/p53** interaction.<sup>13</sup> Along

<sup>a</sup> Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, Berlin 13125, Germany. E-mail: hackenbe@fmp-berlin.de

<sup>b</sup> Novartis Institutes for BioMedical Research, Novartis Campus, Basel CH-4056, Switzerland. E-mail: andreas.marzinzik@novartis.com

<sup>c</sup> PeptiDream, 3-25-23 Tonomachi, Kawasaki-Ku, Kanagawa 210-0821, Japan

<sup>d</sup> Humboldt Universität zu Berlin, Institut für Chemie, Brook-Taylor-Str. 2, Berlin 12489, Germany

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1cb00056j



those lines, very recently it was demonstrated that conjugation of cCPPs *via* triazole linkages to the peptide KD3, which was known to be a non-cell permeable stapled peptide inhibitor of p53/MDM2 and p53/MDMX interactions,<sup>14</sup> enables activation of apoptosis in cancer cells.<sup>15</sup> Alternative approaches for creating cell-permeable peptides to disrupt p53/MDMX interactions using cyclic peptide scaffolds,<sup>16</sup> polycationic tags or medchem optimization strategies have been extensively studied.<sup>17,18</sup>

The aforementioned examples show that peptides create not only important opportunities as tool compounds for assay development and protein structure determination, but can also lead to the discovery of new binding pockets for pharmacophore mapping, even if those peptides are non-permeable. Such discoveries are fueled by the engineering of several peptide display technologies based on non-natural amino acids or in combination with chemical modification strategies, which have opened up fruitful avenues to identify ligands for difficult targets and explore their biological function.<sup>19–22</sup> Still, a straightforward process of identifying and—if necessary—subsequently transforming non-permeable into permeable macrocyclic peptides would significantly extend the PPI repertoire, in particular for enabling intracellular target validation.

In this work we address this challenge and combine the screening of *in vitro*-translated macrocyclic peptides using mRNA display with a chemical modification strategy by cCPP-conjugation to identify highly potent cell-permeable macrocycles on a pharmacological target of central importance, in our case MDM2. By screening of  $>10^{12}$  *in vitro*-translated macrocyclic peptides, we identified a thioether cyclic peptide that inhibits the interaction between p53 and MDM2 with picomolar potency. Subsequent X-ray crystallography revealed a novel binding mode of the peptide with the MDM2 protein. Finally, a cell-penetrating peptide (CPP)-conjugate of this cyclic peptide exhibited a mechanistic response in a cellular context thus validating the relevance of the new binding mode for drug discovery.

## Results and discussion

### Identification and characterization of a novel MDM2-ligand


mRNA display technologies have become one of the leading strategies to identify macrocyclic peptides against various targets including also more challenging PPIs. Highly diverse libraries of constrained peptides offer a greater chance to generate leads against difficult targets displaying novel pharmacophores with affinities comparable to those of antibodies and stability against degradation by proteolytic enzymes.<sup>23</sup> An efficient Flexizyme enabled hit generation process based on a *in vitro* transcription/translation system has been developed, which enables fast screening of  $>10^{12}$  peptides against an immobilized target.<sup>24</sup> Importantly, the Flexizyme based technology permits the efficient charging of different tRNAs with almost any standard or non-standard amino acid with high efficiency.<sup>25</sup> Cyclization to thioether peptides occurs spontaneously through an incorporated N-terminal residue bearing a

reactive chloro-acetyl group with the thiol from a cysteine side chain located at the C-terminus of the translated peptide. The *in vitro* translation system combined with the Flexizyme-mediated reprogramming of the genetic code has been previously described<sup>26</sup> and the details of the selection conditions are provided in the ESI† (Section S4).

Immobilized MDM2 was screened *versus in vitro* translated peptides containing a standard set of natural amino acids (Ser, Tyr, Pro, His, Arg, Thr, Asn, Val, Asp, Gly and Cys), along with the non-natural elongators *N*-methyl-Ser (MeS), *N*-methyl-Phe, *N*-methyl-Gly, *N*-methyl-Ala, and biphenylalanine (B). *N*-Chloroacetyl L-Phe was used in place of the initiator methionine to enable spontaneous cyclization with Cys to form thioether-cyclized peptides during the translation process (ESI,† Fig. S2). Selection and translation were performed in an iterative manner and the amino acid hit sequences were identified by next-generation sequencing. The amino acid sequence of the most enriched hit was selected for chemical synthesis and the corresponding peptide macrocycle CMR19 (Fig. 1) was generated from the linear precursor by capping the N-terminal residue with chloro-acetyl and subsequent robust ring-closure onto a Cys side chain (see ESI†). CMR19 displays a N-terminal phenylalanine-serine sequence followed by an acidic Asp residue succeeded by 3 polar Ser residues. While serine in position (4) is the only *N*-methylated amino acid, the serine residues in position 4 and 5 present the regular amide backbone. The next three residues presented are the hydrophobic Val(7), Pro(8), followed by polar Asn(9). Subsequently to two biphenyl at residues at position 10 and 11, Arg and Asn complete the thioether cyclic peptide formed by the Cys(14). The expendable C-terminal Gly is the point of attachment to the RNA during the display and is used as the point of conjugation for dyes or cell penetrating tags.

Initial confirmation of the synthesized ligand was performed by assessing their ability to inhibit the interaction between MDM2 and a p53-derived peptide in a TR-FRET assay. CMR19 exhibited picomolar potency without any medicinal chemistry optimization with an IC<sub>50</sub> value of 0.18 nM (corresponding to the calculated  $K_1$  of 0.15 nM, ESI,† Section S5). In spite of this high potency in a biochemical assay, we did not observe any cytotoxic response when testing CMR19 on the MDM2 dependent SJS-1 cells up to 30 μM. The efficiency of the ligand discovery process is shown by the fact that the highly optimized clinical small molecule inhibitor CGM097 only shows 1.7 nM potency ( $K_1 = 1.4$  nM) in the same p53 displacement assay (MDM4 TR-FRET  $K_1 = 1950$  nM). The macrocycle shows  $>4000$  fold selectivity for MDM2 ( $K_1 = 0.15$  nM) compared to MDM4 ( $K_1 = 740$  nM). Differences in binding selectivity were also previously observed for optimized stapled KD3-peptides with picomolar affinity for MDM2, and  $\sim 1$  nM activity for MDM4.<sup>15</sup> Due to the presence of hydrophobic pockets in the p53 binding site on MDM2, we speculated that the two biphenyl moieties may form key pharmacophores for the high binding affinity observed. Indeed, design of an inactive mutant was achieved by exchanging the biphenyl amino acid in position 11 with an Ala. The B11A mutant MMS95





**Fig. 1** Chemical structure, **MDM2/4** TR-FRET  $IC_{50}$  data, and SJSA  $EC_{50}$  cell data of macrocyclic peptide **CMR19** identified from *in vitro* selection and of the inactive (B11A) mutant **MMS95**. Blue color indicates non-natural amino acids in the hit sequence and red color indicates terminal Gly used as spacer for attachment of cell penetrating moieties.

showed no activity in the p53-displacement assay (> 10  $\mu$ M) nor on SJSA cells (> 30  $\mu$ M).

### Co-crystal structure of CMR19 with MDM2

The first crystal structure of **MDM2** bound to a 15-residue transactivation domain peptide of p53 had shown that **MDM2** has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic  $\alpha$ -helix.<sup>27</sup> Three key amino acids covering the triad of p53 amino acids Phe19, Trp23, and Leu26 insert deeply into the **MDM2** clefts by hydrophobic interactions.

The co-crystal structure of ligand **CMR19** in complex with **MDM2** (Fig. 2) revealed that the non-canonical biphenyl side chains in positions 10 and 11 occupy the Leu- and Trp-pockets of **MDM2**. Interestingly, the Phe-pocket of **MDM2** is less occupied by Val(7) of **CMR19** than the Phe of p53 in **MDM2**.<sup>28</sup> Both biphenyls are penetrating deeply into the **MDM2** protein. The almost parallel arrangement of the adjacent biphenyls is stabilized by an edge-to-face interaction between the opposite aromatic rings. All amides of the **CMR19** backbone are in *trans* configuration including the *N*-methylated Ser(4), except Pro(8) is *cis*. In comparison with the X-ray of the clinically evaluated **CGM097** (white structure in Fig. 2B) the biphenyl group (10) of **CMR19** (blue structure) penetrates more deeply into Leu-pocket than corresponding group of **CGM097**.

Interestingly, a substantial part of **CMR19** is not involved in direct binding interaction with **MDM2** (Fig. 2C). There is a complex intramolecular hydrogen bonding network in place that stabilizes the distinct conformation of the peptide and directs the three main pharmacophoric substituents. Solvent exposed polar amino acids Ser(2) and Asn(13) are not part of that network whereas hydrogen bonds between the polar side chains of Asp(3), Ser(5), Ser(6), Asn(9), and Arg(12) and the backbone of the macrocycle are. In addition, several

intramolecular hydrogen bonds between backbone CO and backbone NH are stabilizing the conformation, e.g. NH of Arg(12) with CO of Pro(8), NH of Cys(14) with CO of B(11), and NH of Phe(1) with CO of B(10).


**CMR19** makes additional critical contacts with **MDM2** (Fig. 2D), including hydrogen bonds between the backbone NH of Val(7) and the backbone CO-Gln(72) (distance 2.9 Å), between the side chain OH of MeS(4) and the side chain of His(96) (distance 2.7 Å), and the backbone CO of MeS(4) and the side chain of K(94) (distance 2.9 Å). Additional figures illustrating the interactions (and electron density) are shown in the ESI<sup>†</sup> and a pymol-session file is included in the ESI.<sup>†</sup> His(96) of **MDM2** is replaced in **MDM4** by a proline residue, so the **CMR19** side chains of MeS(4) and the bi-phenyl(10) cannot form the key interactions, which correlates with the more than thousand fold loss in affinity.

During the screening process the C-terminal Gly is the point of attachment to the oligonucleotide linking the genotype to the phenotype and any attachment to the Gly usually does not interfere with the binding to the protein. This is evident from the crystal structure showing that the C-terminal amide is pointing vertically away from the protein (left part of ligand above Phe(1) in Fig. 2C). In general, C-terminal modifications of thioether macrocyclic peptides have been described as strategies for transitioning peptides to cell permeable leads.<sup>29</sup>

### Cellular uptake of CPP-conjugated peptide inhibitors

The generated **MDM2**-inhibitor and the negative control were functionalized at the C-terminus to confer cell-permeability. Cell-penetrating peptides (CPPs) are useful tools that have been used to transport a variety of cargoes into cells.<sup>30–32</sup> Alternatively, reactive disulfides have also been shown to enable the cellular delivery of peptide cargoes.<sup>33</sup> Both options were





**Fig. 2** X-Ray structure of **CMR19** in complex with **MDM2**. (A) Overview showing the N-terminal domain of **MDM2** as a ribbon-model (color ramped from N-terminus in blue to C-terminus in red) and **CMR19** as a stick-model (carbons in cyan, nitrogens in blue, oxygens in red, sulfurs in brown). The Leu- and Trp-pockets of **MDM2** are deeply occupied by biphenyl groups, the Phe-pocket by Val-Pro. (B) Superposition of **CMR19** (carbons in cyan) and the clinical trial compound **CGM097** (carbons in white) bound to **MDM2**. The biphenyl group of **CMR19** penetrates more deeply into the Leu-pocket than the corresponding group of **CGM097**. On the other hand, for **CGM097** the Cl-phenyl makes slightly deeper contacts than the corresponding biphenyl group in the Trp-pocket. The orientation of (B) and (C) is rotated by 180 deg around a vertical axis, relative to (A). (C) **CMR19** (carbons in cyan) forms an intricate intra-molecular hydrogen bond network which stabilizes the **MDM2**-bound conformation. The "upper half" of **CMR19** does not interact with **MDM2** (carbons in yellow) but stabilizes the conformation of the ligand. The non-canonical biphenyl side chains of **CMR19** in positions 10 and 11 occupy the Leu- and Trp-pockets of **MDM2**, while the side chain of Val(7) occupies the Phe-pocket. (D) View rotated by 90 deg towards viewer around a horizontal axis, relative to (C). Selected direct intra- and inter-molecular hydrogen bond interactions are depicted in white (water molecules not shown). **CMR19** makes direct inter-molecular hydrogen bonds between the backbone NH of Val(7) and the backbone CO-Gln(72) (distance 2.9 Å), between the side chain OH of MeS(4) and the side chain of His(96) (distance 2.7 Å), and the backbone CO of MeS(4) and the side chain of K(94) (distance 2.9 Å). The coordinates for **MDM2/CMR19** have been deposited in the PDB databank (PDB access code = 7NUS).

evaluated in the context of this work. For this, derivatives of the **CMR19** and **MMS95** peptides were synthesized either with a cysteine, as a handle for the attachment of a cell-penetrating peptide *via* a disulfide bond, or with asparagusic acid (AspA), a reactive disulfide.<sup>33</sup> As a cell-penetrating peptide, a cyclic deca-arginine (cR10) was used.<sup>34,35</sup> Additionally, to evaluate the cellular uptake of the peptides, fluorescent versions of **CMR19** bearing the cysteine or AspA handles were synthesized (Fig. 3).

For the generation of disulfide-linked conjugates of the inhibitor peptides with the cR10-CPP, the inhibitors were first activated with Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid)). The activated species was purified, followed by addition of the cysteine-functionalized cR10 peptide and another purification by HPLC. Procedures, UV chromatograms and mass spectra showing the purity and identity of the peptides are provided in the ESI.†

The cellular uptake of the fluorescent peptides was evaluated by fluorescence microscopy. The peptides were incubated with **SJSA-1** cells at concentrations ranging from 500 nM to 5  $\mu$ M for 2 hours at 37 °C. The cells were then washed and imaged live using confocal laser scanning microscopy (full dataset in ESI†). Even at the highest concentration, the AspA and unmodified cysteine peptide show barely any intracellular fluorescence, suggesting ineffective cellular uptake (Fig. 4, upper row, and bottom right). The conjugate of the peptide with the cR10-CPP showed intracellular Cy5 fluorescence, which correlated with increasing externally applied concentration (Fig. 4, lower row). At the 500 nM and 1  $\mu$ M concentrations the distribution of the fluorescence within the cell has a punctate pattern, suggesting predominantly endosomal entrapment. At the 5  $\mu$ M concentration the fluorescent pattern observed indicates a broader cytosolic distribution of the peptide. This is in line with previous observations that suggest a








Fig. 3 Structure of the conjugated moieties to **CMR19** and **MMS95**. Gly shown in red indicates the C-terminal Gly spacer next to Cys(14) shown in Fig. 1.




Fig. 4 Cellular uptake of Cy5-modified **CMR19** peptides. **SJS-A-1** cells were treated with the peptides at the indicated concentrations, then counter-stained with Hoechst 33342. Shown are merge images of the Hoechst and Cy5 channels. Scale bars 20 μm.

concentration dependent mode of uptake for cell-penetrating peptides.<sup>36</sup> Based on these results, the CPP-conjugated peptides were chosen as the most promising candidates for further studies.

#### p53-Mediated cytotoxicity of cell-permeable MDM2-inhibitors

Since the **CMR19**-peptide is proposed to block the **MDM2/p53** protein-protein interaction, it should be cytotoxic in the **MDM2**-dependent **SJS-A-1** cell line. We probed the cytotoxicity of the synthesized peptide-inhibitors in cell proliferation assay on **SJS-A-1** cells using the WST-1 assay (Fig. 5 and full graphs

with all tested conditions in ESI,† Fig. S7). As a control, we also tested the inhibitors in the **p53**-mutant cell line **SW-480**, which should not show a cytotoxic effect of the inhibitors.<sup>37</sup> The cells were incubated for 24 hours in presence of varying concentrations of the peptide inhibitors. Additionally, **NVP-CGM097** was used as a positive control.<sup>7</sup>

Only the **CMR19-cR10** conjugate and the positive control showed efficient growth inhibition in **SJS-A-1** cells, with similar  $GI_{50}$  values around 1 μM. The peptide conjugate also showed no growth inhibition in the **SW-480** cell line. The cR10-derivative of the inactive control **MMS95**, which previously showed no






Fig. 5 Cell proliferation assay with **SJSA-1** and **SW-480** cells treated with peptide inhibitors of **MDM2** and the **NVP-CGM097** small molecule.

binding to **MDM2** in the TR-FRET assay, had no growth inhibitory effect in this concentration range on either cell line, and neither did the unmodified AspA-modified inhibitor-peptides, or the cell-penetrating peptide alone (Fig. 5 and ESI,† Fig. S7).

Next, we wanted to confirm that the cytotoxicity occurs by inhibiting **MDM2**. When the **p53/MDM2** interaction is inhibited, the **MDM2** protein accumulates in the nucleus promoting **p53** translation.<sup>38</sup> We treated cells with the cR10-CPP fusions of **CMR19** and **MMS95**, as well as with the positive control **NVP-CGM097** for 4 hours at 37 °C. The cells were then fixed and nuclear **MDM2** was detected using immunofluorescence. As expected based on our previous findings, the small molecule

inhibitor **NVP-CGM097** and the cCPP-conjugated **CMR19** peptide led to an increased enrichment of **MDM2** in the nuclei compared to the DMSO control (Fig. 6a, top 2 rows). In contrast, the inactive mutant **MMS95** did not result in increased nuclear staining (Fig. 6a, lower 2 rows) Additionally, we did not observe unspecific membrane disruption caused by the peptides after 4 hours in **SJSA-1** cells.

Furthermore, by using the Hoechst stain as mask for the nuclei, we could use an automated script to quantify nuclear **MDM2** fluorescence for the different inhibitors at different concentrations (Fig. 6b). We observed that both **NVP-CGM097** and the **CMR19** inhibitors show concentration-dependent enrichment of **MDM2**, while **MMS95** does not.




Fig. 6 Quantification of **MDM2** activation in response to inhibition of **p53:MDM2** interactions by immunofluorescence. (a), Confocal microscopy images of **MDM2**-immunofluorescence in **SJSA-1** cells treated with inhibitor-peptides or **NVP-CGM097** at the indicated concentrations. \* = the fluorescent signal for the **NVP-CGM097** positive control was brighter than for the other inhibitors and so the contrast was set two-fold lower. Scale bars 20 μm. (b), Quantification of nuclear **MDM2** in the immunofluorescence experiment at different inhibitor concentrations. Shown are single values and mean ± SD,  $n = 3$ , \*\* =  $P < 0.005$  in unpaired  $t$ -test.



## Conclusions

In summary, we suggest that our mRNA display based method can be used to screen for highly potent and selective macrocycles against **MDM2**. Expressing peptides containing non-natural amino acids was key to discover a new binding site. To the best of our knowledge, we describe for the first time that two biphenyls and a valine residue mimic the helical arrangement of Phe/Trp/Leu of **p53**. These new pharmacophore represent novel opportunities for the design of small molecule inhibitors of the **p53/MDM2** interaction. For the effective translation of a new binding site or new binding mode into drug discovery efforts, it is important to validate the mechanism of action in a cellular setting. The subsequent chemical conjugation of the cyclic peptide presenting a Cys at the C-terminus with cR10 by disulfide formation is well established and is transferable to essentially all ligands identified by mRNA display. By cellular quantification we have established a pharmacodynamic response of our new inhibitor in cells confirming the relevance of the new pharmacophore in a cellular context. Our work has been complemented by many other discoveries of bioactive macrocycles by mRNA display methods and applications of our method to other intracellular targets are under investigation.<sup>23</sup> Our results demonstrate that the discovery process works well for **MDM2** indicating that a similar approach is feasible for other intracellular PPI targets. Thus, this discovery process could significantly broaden the application of cyclic peptides in evaluating new biological targets, imaging approaches and drug discovery in general.

## Author contributions

A. F. L. S., C. P. R. H. and A. L. M. conceived experiments and wrote the manuscript. A. F. L. S. synthesized and characterized final disulfide peptide conjugates, performed uptake, cell viability and microscopy experiments. P. R., J. O., A. L. M. planned display experiments, analyzed NGS data, and deconvoluted hits that led to the identification of **CMR19**. J. K. performed the X-ray experiments, solved the structure, analysed the data, and co-wrote the manuscript. S. R. developed and performed the SJSA cellular assay. T. M. S. performed TRFRET experiments, analysed the data and commented the manuscript. S. R., S. H., A. L. M. designed peptides, planned the peptide synthesis, and summarized experimental data in the ESI.† S. R. performed the syntheses and the chemical characterization. C. E. D. contributed conceptually to the cell experiments and commented on the manuscript.

## Conflicts of interest

The authors declare no competing financial interest.

## Acknowledgements

We acknowledge Aude Izaac, Rene Hemmig, Matteo Fischer, and K. Kemnitz-Hassanin for their excellent technical

assistance. The crystallographic experiments were performed on the X10SA beamline at the Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland. This work was supported by grants from the Deutsche Forschungsgemeinschaft (SPP 1623 and RTG 2473, Projektnummer: 392923329) to C. P. R. H. (HA 4468/9-1, 9-2), the GIF, the German-Israeli Foundation for Scientific Research and Development, and the Fonds der Chemischen Industrie (FCI) to C. P. R. H. and A. F. L. S. (Chemiefonds fellowship).

## References

- 1 D. E. Scott, A. R. Bayly, C. Abell and J. Skidmore, *Nat. Rev. Drug Discovery*, 2016, **15**, 533–550.
- 2 H. Lu, Q. Zhou, J. He, Z. Jiang, C. Peng, R. Tong and J. Shi, *Signal Transduction Targeted Ther.*, 2020, **5**, 213.
- 3 N. Papadantonakis and H. P. Erba, *Adv. Cell Gene Ther.*, 2020, **3**.
- 4 D. Schumacher, J. Helma, A. F. L. Schneider, H. Leonhardt and C. P. R. Hackenberger, *Angew. Chem., Int. Ed.*, 2018, **57**, 2314–2333.
- 5 S. Du, S. S. Liew, L. Li and S. Q. Yao, *J. Am. Chem. Soc.*, 2018, **140**, 15986–15996.
- 6 K. R. Patel and H. D. Patel, *Curr. Med. Chem.*, 2020, **27**, 3706–3734.
- 7 P. Holzer, K. Masuya, P. Furet, J. Kallen, T. Valat-Stachyra, S. Ferretti, J. Berghausen, M. Bouisset-Leonard, N. Buschmann, C. Pissot-Soldermann, C. Rynn, S. Ruetz, S. Stutz, P. Chene, S. Jeay and F. Gessier, *J. Med. Chem.*, 2015, **58**, 6348–6358.
- 8 M. Pazgier, M. Liu, G. Zou, W. Yuan, C. Li, C. Li, J. Li, J. Monbo, D. Zella, S. G. Tarasov and W. Lu, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 4665–4670.
- 9 Y. S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K. H. To, K. A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. Elkin, Z. Filipovic, F. Z. Qureshi, H. L. Cai, P. Berry, E. Feyfant, X. G. E. Shi, J. Horstick, D. A. Annis, A. M. Manning, N. Fotouhi, H. Nash, L. T. Vassilev and T. K. Sawyer, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, E3445–E3454.
- 10 M. N. Saleh, M. R. Patel, T. M. Bauer, S. Goel, G. S. Falchook, G. I. Shapiro, K. Y. Chung, J. R. Infante, R. M. Conry, G. Rabinowits, D. S. Hong, J. S. Wang, U. Steidl, G. Naik, V. Guerlavais, V. Vukovic, D. A. Annis, M. Aivado and F. Meric-Bernstam, *Clin. Cancer Res.*, 2021, DOI: 10.1158/1078-0432.CCR-21-0715.
- 11 T. Okamoto, K. Zobel, A. Fedorova, C. Quan, H. Yang, W. J. Fairbrother, D. C. Huang, B. J. Smith, K. Deshayes and P. E. Czabotar, *ACS Chem. Biol.*, 2013, **8**, 297–302.
- 12 Q. Chu, R. E. Moellering, G. J. Hilinski, Y. W. Kim, T. N. Grossmann, J. T. H. Yeh and G. L. Verdine, *MedChemComm*, 2015, **6**, 111–119.
- 13 P. G. Dougherty, J. Wen, X. Pan, A. Koley, J. G. Ren, A. Sahni, R. Basu, H. Salim, G. Appiah Kubi, Z. Qian and D. Pei, *J. Med. Chem.*, 2019, **62**, 10098–10107.



- 14 G. Philippe, Y. H. Huang, O. Cheneval, N. Lawrence, Z. Zhang, D. P. Fairlie, D. J. Craik, A. D. de Araujo and S. T. Henriques, *Biopolymers*, 2016, **106**, 853–863.
- 15 G. J. Philippe, A. Mittermeier, N. Lawrence, Y. H. Huang, N. D. Condon, A. Loewer, D. J. Craik and S. T. Henriques, *ACS Chem. Biol.*, 2021, **16**, 414–428.
- 16 N. Lawrence, G. J.-B. Philippe, P. J. Harvey, N. D. Condon, A. H. Benfield, O. Cheneval, D. J. Craik and S. Troeira Henriques, *RSC Chem. Biol.*, 2020, **1**, 405–420.
- 17 L. K. Buckton, M. N. Rahimi and S. R. McAlpine, *Chemistry*, 2021, **27**(5), 1487–1513.
- 18 M. R. Naylor, A. T. Bockus, M. J. Blanco and R. S. Lokey, *Curr. Opin. Chem. Biol.*, 2017, **38**, 141–147.
- 19 Z. Zhang, R. Gao, Q. Hu, H. Peacock, D. M. Peacock, S. Dai, K. M. Shokat and H. Suga, *ACS Cent. Sci.*, 2020, **6**, 1753–1761.
- 20 J. E. Townend and A. Tavassoli, *ACS Chem. Biol.*, 2016, **11**, 1624–1630.
- 21 S. Kalhor-Monfared, M. R. Jafari, J. T. Patterson, P. I. Kitov, J. J. Dwyer, J. M. Nuss and R. Derda, *Chem. Sci.*, 2016, **7**, 3785–3790.
- 22 K. Maola, J. Wilbs, J. Touati, M. Sabisz, X. D. Kong, A. Baumann, K. Deyle and C. Heinis, *Angew. Chem., Int. Ed.*, 2019, **58**, 11801–11805.
- 23 Y. Huang, M. M. Wiedmann and H. Suga, *Chem. Rev.*, 2019, **119**, 10360–10391.
- 24 K. Kashiwagi and P. C. Reid, *US Pat.*, *US2012/208720*, 2012.
- 25 Y. Goto, T. Katoh and H. Suga, *Nat. Protoc.*, 2011, **6**, 779–790.
- 26 T. Ishizawa, T. Kawakami, P. C. Reid and H. Murakami, *J. Am. Chem. Soc.*, 2013, **135**, 5433–5440.
- 27 P. H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine and N. P. Pavletich, *Science*, 1996, **274**, 948–953.
- 28 J. Kallen, A. Izaac, S. Chau, E. Wirth, J. Schoepfer, R. Mah, A. Schlapbach, S. Stutz, A. Vaupel, V. Guagnano, K. Masuya, T. M. Stachyra, B. Salem, P. Chene, F. Gessier, P. Holzer and P. Furet, *ChemMedChem*, 2019, **14**, 1305–1314.
- 29 L. J. Walport, R. Obexer and H. Suga, *Curr. Opin. Biotechnol.*, 2017, **48**, 242–250.
- 30 H. Derakhshankhah and S. Jafari, *Biomed. Pharmacother.*, 2018, **108**, 1090–1096.
- 31 A. Falanga, L. Lombardi, E. Galdiero, V. D. Genio and S. Galdiero, *Future Med. Chem.*, 2020, **12**, 1431–1446.
- 32 N. Nischan, H. D. Herce, F. Natale, N. Bohlke, N. Budisa, M. C. Cardoso and C. P. Hackenberger, *Angew. Chem., Int. Ed.*, 2015, **54**, 1950–1953.
- 33 G. Gasparini, G. Sargsyan, E. K. Bang, N. Sakai and S. Matile, *Angew. Chem., Int. Ed.*, 2015, **54**, 7328–7331.
- 34 H. D. Herce, D. Schumacher, A. F. L. Schneider, A. K. Ludwig, F. A. Mann, M. Fillies, M. A. Kasper, S. Reinke, E. Krause, H. Leonhardt, M. C. Cardoso and C. P. R. Hackenberger, *Nat. Chem.*, 2017, **9**, 762–771.
- 35 A. F. L. Schneider, A. L. D. Wallabregue, L. Franz and C. P. R. Hackenberger, *Bioconjugate Chem.*, 2019, **30**, 400–404.
- 36 F. Duchardt, M. Fotin-Mleczek, H. Schwarz, R. Fischer and R. Brock, *Traffic*, 2007, **8**, 848–866.
- 37 L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi and E. A. Liu, *Science*, 2004, **303**, 844–848.
- 38 M. Gajjar, M. M. Candeias, L. Malbert-Colas, A. Mazars, J. Fujita, V. Olivares-Illana and R. Fahraeus, *Cancer Cell*, 2012, **21**, 25–35.

